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Abstract
Background The mitogen-activated protein kinases 1 and
2 (MEK1, MEK2) are fundamental partners in the RAS–
RAF–MEK–ERK pathway that is involved in regulation of
cell proliferation, differentiation and survival. Downregu-
lation of the MEK cascades has been implicated in
acquiring of the malignant phenotype in various cancers.
Somatic mutations in MEK1 gene (substitutions K57N,
Q56P, D67N) were described in \1 % of non-small cell
lung cancer (NSCLC) and they were more commonly
reported in adenocarcinoma patients with current or former
smoking status.
Materials and methods In the following study, we
assessed the MEK1 gene mutations in 145 FFPE tissue
samples from central nervous system (CNS) metastases of
NSCLC using HRM-PCR and ASP-qPCR techniques. The
studied group was heterogeneous in terms of histopathol-
ogy and smoking status. The prevalence of the MEK1 gene
mutation was correlated with the occurrence of mutations
in KRAS, EGFR, DDR2, PIK3CA, NRAS, HER2, AKT1 and
PTEN genes.
Results Using HRM and ASP-qPCR methods we identi-
fied one (0.7 %; 1/145) MEK1 substitution (Q56P) in CNS
metastases of NSCLC. The mutation was identified in a
single, 50-year-old, current smoking men with adenocar-
cinoma (1.25 %; 1/80 of all adenocarcinomas).
Conclusions According to the current knowledge, the
incidence of MEK1 gene mutation in CNS metastatic lesion
of NSCLC is the first such report worldwide. The analysis
of gene profile in cancer patients may extend the scope of
molecularly targeted therapies used both in patients with
primary and metastatic tumors of NSCLC.
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Abbreviations
ASP-qPCR Allele-specific quantitative polymerase chain
reaction
CNS Central nervous system
FFPE Formalin fixed paraffin embedded
HRM High-resolution melting
MEK1 Mitogen-activated protein kinase 1
mt Mutant type





The mitogen-activated protein kinase (MAP2K, MEK) is
dual specificity kinase of the MAPK and STE7 stimulated
by the binding of mitogens, hormones, or neurotransmitters
[1–3]. Both the MEK1 and MEK2 kinases are fundamental
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partners in the MAPK/ERK pathway (RAS–RAF–MEK–
ERK) that regulates cell activities, including proliferation,
transcriptional regulation, differentiation, and survival [4–
6]. Deregulation of kinase cascades involved in the MAPK/
ERK pathway is observed in several cancers and leads to
uncontrolled cell differentiation, proliferation, migration,
and angiogenesis [1–6]. Somatic mutations in MEK1 gene
that affect the MAPK/ERK pathway were described in
\1 % of non-small cell lung cancer (NSCLC) and they are
more commonly reported in adenocarcinoma than squa-
mous cell carcinoma, smokers or former smokers, and their
presence was not associated with age, gender, race or
disease stage [2, 7–10]. The most frequent MEK1 muta-
tions in NSCLC are described as amino acids substitutions
(K57N, Q56P, D67N) located in exon 2 and they are
mutually exclusive with other driver mutations [7–10].
MEK1 gene mutations are referred as a rare event in
NSCLC, and its clinical usefulness as a therapeutic target
or indicators for drug resistance in NSCLC is still debat-
able [11]. However, there are some data that proved
effectiveness of MEK pathway-targeted treatment. MEK
inhibitors (selumetinib and trametinib) have showed
promising antitumor effects in patients harboring mutations
in RAS or RAF genes in different cancer types. Trametinib
was approved in 2013 as a single agent for treatment of
BRAF V600E or V600K mutation-positive unresectable or
metastatic melanoma and in 2015 in combination with
dabrafenib for treatment of such patients [6, 12].
In the future, the presence of the substitutions Q56P,
K57N and D67N in MEK1 gene would be a potential
predictive marker of agents targeted to RAS–RAF–MEK–
ERK pathways and their evaluation may play a role in
therapy designing. It is debatable, if patients with meta-
static lesions of NSCLC could be treated with molecularly
targeted therapies or such therapies should be limited only
to primary tumors. The central nervous system (CNS)
metastases are the most frequent location of metastases in
NSCLC after the lymph nodes. Unfortunately, there are
limited evidences about the prevalence of MEK1 gene
mutations in metastatic lesions of NSCLC.
Materials and methods
Patients
145 formalin-fixed paraffin-embedded (FFPE) tissue sam-
ples were obtained from Caucasian patients with CNS
metastases of advanced NSCLC as well as from 30 corre-
sponding primary NSCLC tumors. The patients underwent
routine neurosurgical procedures with a palliative manner.
The median overall survival (OS) was 13.5 months (range
0.1–78.2 months—information available from 119 patients).
Detailed characteristics of studied group have been pre-
sented in Table 1. The study was approved by the Ethics
Committee of the Medical University of Lublin, Poland (No.
KE-0254/86/2013).
Mutation analysis
DNA was isolated from FFPE metastatic tissue samples
using QIAamp DNA FFPE Tissue Kit (Qiagen, USA)
according to manufacturer’s protocol. The MEK1 gene
mutations were screened using High-Resolution Melting
PCR (HRM-PCR) technique. Type of substitution (Q56P,
K57N and D67N) was identified in the Allele-Specific
quantitative PCR (ASP-qPCR). In both reactions we used
GoTaq qPCR Master Mix (Promega, USA). Total volume
of HRM and ASP-qPCR reactions mixture (15 ll) con-
tained: 8 ll of GoTaq qPCR Master Mix, 1 ll of purified
genomic DNA (20 ng/ll), 1 ll of each forward and reverse
primers and 4 ll of nuclease-free water. The amplification
was performed in 48-well plates using the Eco real-time
PCR device (Illumina, USA). PCR for HRM procedure was
performed using one pair of primers flanking the mutated
sides in exon 2 of the MEK1 gene in following steps: pre-
denaturation 95 C—10 min and 45 cycles in conditions:
95 C—15 s and 62 C—60 s. The high-resolution melting
procedure was performed for PCR products in following
amplitudes of temperature: 92 C—5 s, 72—20 s,
Table 1 Studied group characteristic
Gender
Male, n (%) 100 (69)
Female, n (%) 45 (31)
Age
Median age ± SD (years) 60 ± 8.8
C60 years, n (%) 72 (49.7)
\60 years, n (%) 73 (50.3)
Histopathology
Adenocarcinoma, n (%) 80 (55.2)
Squamous cell carcinoma, n (%) 29 (20)
Large cell carcinoma, n (%) 22 (15.1)
NSCLC-NOS, n (%) 14 (9.7)
Smoking status
Current smokers, n (%) 73 (50.4)
Former smokers, n (%) 21 (14.5)
Non-smokers, n (%) 36 (24.8)
Lack of data, n (%) 15 (10.3)
Performance status (PS)
0, n (%) 22 (15.2)
1, n (%) 76 (52.4)
2, n (%) 31 (21.4)
3, n (%) 16 (11)
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92 C—5 s. ASP-qPCR was performed in whole studied
group and allowed to determine the type of mutation
detected in HRM-PCR analysis. The mt and wt of MEK1
gene were tested in separate reactions with allele-specific
forwards primers. The amplification of examined region
was performed in following steps: pre-denaturation
95 C—10 min. and 35 cycles in conditions: 95 C—15 s
and 64 C—60 s. Samples were assessed as positive if
amplification in the ASP-qPCR was observed both for mt
and for wt of MEK1 gene. The samples with late amplifi-
cation (Ct[ 32 cycle) of wt MEK1 gene were excluded
from analysis and the analysis was repeated. Samples with
late amplification (Ct[ 32 cycle) of mt region of MEK1
gene were assessed as negative. DNA isolated from
peripheral blood leukocytes of healthy individuals
(n = 10) provide the negative control of analysis.
Results
HRM-PCR analysis allowed amplification of selected
MEK1 gene region located in exon 2 both in all analyzed
samples (mean Ct = 25th cycle). Based on the differences
in amplification and melting curves of studied samples and
negative controls, we were able to distinguish (Fig. 1)
mutant (mt) and wild (wt) of the MEK1 gene. Based on
HRM-PCR, we detected one positive sample. The ASP-
qPCR (Fig. 2) was performed in all examined samples and
confirmed results obtained in HRM-PCR. Using of well-
known pairs of primers dedicated for mt and wt regions the
ASP-qPCR technique allowed us to identify the type of
detected substitution (Q56P). In other samples and in
negative control only the amplification of wt MEK1 was
observed (mean Ct = 20th cycle). All available corre-
sponding primary tumors had been determined as wt of
MEK1 gene in both techniques.
Q56P substitution in exon 2 of MEK1 gene was detected
in NSCLC metastasis into CNS of single male patient
[0.7 % (1/145) of all analyzed patients; 1 % (1/100) of
male patients]. Unfortunately, the corresponding primary
tumor was not available from this patient. The patient was
a 50-year-old smoker [80 pack-years; 1.1 % (1/94) of
smokers] with advanced (IV stage) primary lung adeno-
carcinoma [1.25 % (1/80) of adenocarcinoma patients]. His
survival time from diagnosis to death was 20.5 months.
The time between development of primary and metastatic
lesion was 15.7 months.
Additionally, in previous studies we reported the inci-
dence of KRAS (23 %), EGFR (6 %), DDR2 (2 %), PIK3CA
(2 %), NRAS (1.5 %), HER2 (\1 %), AKT1 (\1 %) and
PTEN (\1 %) genes mutations in CNS metastases of
NSCLC. None of these mutations coexisted with a 184
mutation in MEK1 gene that was detected in this analysis.
However, the assessment of more samples could confirm
Fig. 1 Differences in melting
curves of MEK1 wt and mt
genotypes. The Q56P mutation
involves replacing of the
adenine (wt) by cytosine (mt) in
the 167 position of MEK1 gene
(exon 2). Comparison of
melting temperatures and
analysis of normalized data
plots allowed to distinguish wt
and mt of MEK1 gene. The
melting curve 1 represents wt
MEK1 region which
corresponds to the adenine in
the position 167. The melting
curve 2 represents mt MEK1
region which corresponds to the
cytosine in the position 167 that
needs higher temperature to
melt the qPCR products
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mutual exclusivity of CNS metastatic lesions of NSLC. Also
analysis of fresh frozen samples rather than FFPE blocks
might allow to avoid bias of the study which could lead to
identification of large number of MEK1 mutations.
Discussion
The presented article has shown that rare MEK1 gene
mutations could be detected in CNS metastatic lesions of
NSCLC, which to our knowledge is the first such report
worldwide. In the following study we indicated only one
MEK1 gene mutation (Q56P) at metastatic lesion of patient
who had diagnosed lung adenocarcinoma. Moreover, the
patient declared himself as a current smoker (80 pack-
years). Q56P mutation was mutually exclusive with all
other alterations previously tested in this studied group.
Till date, only several reports have been published about
the incidence of MEK1 gene mutations in primary tumors
of NSCLC [7–10]. Low frequency (\1 %) of this mutation
creates difficulties to define the molecular, clinical and
pathologic characteristics of patients who are carriers of
MEK1 mutation [7, 9]. In 2008, Marks et al. [8] published
first report about the presence of somatic mutations (two
K57 N substitutions) in MEK1 in NSCLC primary tumors.
Despite adenocarcinoma histology of positive patients, the
MEK1 mutations were related to smoking status (former
smokers) and both patients were followed up for 4 years
which was also connected with early stage (IA) of the
disease. Arcila et al. [7] also selected a small group of
adenocarcinoma NSCLC patients (26/5330; 0.6 %) with
MEK1 gene mutation. The most common substitutions
were described as K57N and Q56P (20/26 and 6/26,
respectively). No D67 N substitution was observed. All
positive patients were former or current smokers and their
median pack-year history of smoking was 48. Kris et al. [9]
in the multi-center study mentioned about two MEK1
positive adenocarcinoma patients, but their report limited
only to the frequency (0.2 %) of the MEK1 mutation and
any specific characteristic of these patients was not
described. Similarly, in the Cancer Genome Atlas Research
Network study two (2/230) MEK1 gene mutations were
identified in adenocarcinoma NSCLC without clinical
characteristic of patients [10]. Because of MEK1 muta-
tions’ rarity only the frequency (without specifying their
type) was noted in both analysis [9, 10]. Also, Zhou et al.
[11] reported three (0.8 %) MEK1 gene-mutated tumors,
where two of them were described as squamous cell lung
carcinoma. In all above-cited papers the MEK1 positive
tumors were mutually exclusive with all other genetic
alterations, including known activating mutations in
EGFR, KRAS, HER2, NRAS and BRAF genes [7, 11].
There is limited number of study about effectiveness of
anti-MEK1 agents in NSCLC patients that proved their
activity in combinations with chemotherapy or in
monotherapy. Moreover, efficacy of EGFR- and BRAF-
targeted drugs has not been sufficiently investigated in
MEK1-mutated patients [5, 12, 13]. There are some MEK
inhibitors (selumetinib and trametinib) that showed
promising antitumor effects in various cancers including
melanoma and NSCLC with RAS/RAF disorders. Trame-
tinib showed favorable clinical efficacy in a phase III trial
in treatment of BRAF-mutated melanoma patients in
comparison to chemotherapy [median progression-free
survival (PFS) was 4.8 vs 1.5 months (p\ 0.001);
6 months OS was 81 vs 67 % (p\ 0.01)] [4]. Trametinib
monotherapy activity was also observed in RAS-mutant
NSCLC patients (partial response—7 % and stable dis-
ease—53 % of patients) [14]. However, Blumenschein
et al. showed no superiority in trametinib with docetaxel
compared with docetaxel alone as a second-line therapy in
previously treated KRAS-mutant NSCLC patients [5].
Janne et al. [15] showed an improvement in both PFS and
ORR with the combination of selumetinib and docetaxel
(vs docetaxel alone) in patients with KRAS-mutant
NSCLC. Also pimasertib (AS703026, MSC1936369B)
may be used as noncompetitive second-generation inhibitor
of MEK in RAS/RAF-mutated solid tumors [13, 16]. Qu
et al. [13] suggested that the combination of MEK-TKI and
Fig. 2 Amplification curves of MEK1 gene in ASP-qPCR analysis.
Curve 1 represents amplification of wt MEK1 region in negative
control. Curve 3 represents lack of amplification mt MEK1 region in
negative control. Curve 2 represents amplification of mt MEK1 region
in positive patient
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a PIK3/mTOR-TKI may be effective in controlling of
chemotherapy-resistant tumors.
Based on the overall data we would like to conclude that
the MEK1 gene mutations could be detectable in the CNS
metastatic lesions of NSCLC. However, it needs more
studies to confirm if MEK1 mutations can be preferably
present in CNS metastases of adenocarcinoma and in
patients with smoking status, like it was described in pri-
mary NSCLC tumors. The analysis of gene profile in
cancer patients may extend the scope of molecularly tar-
geted therapies used both in patients with primary and
metastatic NSCLC. Moreover, in the near future, the per-
sonalized therapy based on the assessment of different gene
mutations in NSCLC patients may become a reality.
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